Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-vWF Nanobody that is in Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, an anti-RSV Nanobody, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus (RSV) infection; and Vobarilizumab, an anti-IL-6R Nanobody that is in Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as auto-immune disorders; ozoralizumab, which is in a Phase IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone related disorders, including osteoporosis and bone metastases, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaborations with AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk, and Taisho Pharmaceuticals. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for ABLYF